Effects of leflunomide on immune responses and models of inflammation - PubMed (original) (raw)

Review

Effects of leflunomide on immune responses and models of inflammation

R R Bartlett et al. Springer Semin Immunopathol. 1993.

No abstract available

PubMed Disclaimer

Similar articles

• Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.
  Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rüde E, Thoenes GH, Küchle CC, Schorlemmer HU, Bremer E, et al. Bartlett RR, et al. Agents Actions. 1991 Jan;32(1-2):10-21. doi: 10.1007/BF01983301. Agents Actions. 1991. PMID: 2058454 Review.
• Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
  Bartlett RR, Brendel S, Zielinski T, Schorlemmer HU. Bartlett RR, et al. Transplant Proc. 1996 Dec;28(6):3074-8. Transplant Proc. 1996. PMID: 8962190 Review. No abstract available.
• Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
  Herrmann ML, Schleyerbach R, Kirschbaum BJ. Herrmann ML, et al. Immunopharmacology. 2000 May;47(2-3):273-89. doi: 10.1016/s0162-3109(00)00191-0. Immunopharmacology. 2000. PMID: 10878294 Review.
• Complete control of humoral and cell-mediated xenoreactions with the combination of leflunomide and cyclosporine.
  Chong AS, Shen J, Xiao F, Blinder L, Foster P, Sankary H, Williams JW. Chong AS, et al. Transplant Proc. 1996 Apr;28(2):684. Transplant Proc. 1996. PMID: 8623344 No abstract available.
• Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
  Pinschewer DD, Ochsenbein AF, Fehr T, Zinkernagel RM. Pinschewer DD, et al. Transplantation. 2001 Aug 27;72(4):712-9. doi: 10.1097/00007890-200108270-00026. Transplantation. 2001. PMID: 11544436

Cited by

• [80 milestones in rheumatology from 80 years- III. 1980-2000].
  Burmester GR, Kalden JR, Rose T. Burmester GR, et al. Z Rheumatol. 2021 Aug;80(6):515-527. doi: 10.1007/s00393-021-01037-9. Epub 2021 Jul 8. Z Rheumatol. 2021. PMID: 34236494 Review. German. No abstract available.
• Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease?
  Vijaysekharan K, Punatar S, Bonda A, Mohite A, Shanmugam K, Nayak L, Gokarn A, Khattry N. Vijaysekharan K, et al. Indian J Hematol Blood Transfus. 2018 Jul;34(3):566-567. doi: 10.1007/s12288-018-0929-x. Epub 2018 Feb 12. Indian J Hematol Blood Transfus. 2018. PMID: 30127579 Free PMC article. No abstract available.
• From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
  Aly L, Hemmer B, Korn T. Aly L, et al. Curr Neuropharmacol. 2017;15(6):874-891. doi: 10.2174/1570159X14666161208151525. Curr Neuropharmacol. 2017. PMID: 27928949 Free PMC article. Review.
• Risk stratification and mitigation multiple sclerosis.
  Ontaneda D, Cohn S, Fox R. Ontaneda D, et al. Mult Scler Relat Disord. 2014 Sep;3(5):639-49. doi: 10.1016/j.msard.2014.05.003. Mult Scler Relat Disord. 2014. PMID: 25221744 Free PMC article. Review.
• Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats.
  Kayhan S, Guzel A, Duran L, Tutuncu S, Guzel A, Gunaydın M, Salis O, Okuyucu A, Selcuk MY. Kayhan S, et al. J Thorac Dis. 2013 Oct;5(5):641-9. doi: 10.3978/j.issn.2072-1439.2013.09.20. J Thorac Dis. 2013. PMID: 24255778 Free PMC article.

References

1. 1. Blood. 1990 Jan 1;75(1):88-95 - PubMed
2. 1. Agents Actions. 1986 Dec;19(5-6):313-4 - PubMed
3. 1. Scand J Rheumatol Suppl. 1988;75:290-9 - PubMed
4. 1. Arthritis Rheum. 1987 Feb;30(2):201-12 - PubMed
5. 1. Int J Immunopharmacol. 1985;7(1):7-18 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations